Medication Trends in Australian Workers' Compensation 2026

What prescribers are actually doing, what evidence supports, and what shifts your claims strategy

Published 3 April 2026

The Prescribing Landscape Has Changed

You're managing a workers compensation cohort that looks different from five years ago. Your claimants are taking different medications, in different combinations, at different doses. Some of these changes reflect genuine evidence-based advancement. Others represent drift. Your challenge as claims manager is distinguishing between the two, because your claims strategy depends on it.

The medication patterns emerging in Australian workers compensation claims in 2026 tell a story about how treatment approaches have evolved, where prescribers are confident, where they're uncertain, and where cost pressures are driving decisions. Understanding these trends allows you to anticipate problems before they become entrenched in your claims.

Gabapentinoids: The Trend You Can't Ignore

Pregabalin and gabapentin prescribing in workers compensation has intensified. You see these medications escalating rapidly, particularly in musculoskeletal and neuropathic pain presentations. What's notable is not that these medications are being used, but the pattern of their use: higher doses, longer durations, and increasing resistance to deprescribing when claims enter chronic phases.

Your prescribers are reaching for gabapentinoids earlier and holding them longer. The clinical justification is often straightforward: nerve pain is difficult to manage, and these medications work for some patients. But you should be alert to patterns where gabapentinoids have become the default rather than the evidence-based choice for a specific indication. When every claimant with any neuropathic symptoms receives escalating doses of pregabalin, you're looking at habit rather than precision medicine.

Opioid Deprescribing: Progress, But Inconsistent

The good news is that opioid prescribing is declining in workers compensation populations. You're seeing fewer claimants initiated on opioids, and you're seeing more prescribers willing to deprescribe when claims reach chronic phases. This represents genuine progress in evidence-based pain management.

However, your experience likely shows that this progress is inconsistent. Some prescribers have embraced opioid-sparing approaches entirely. Others maintain significant opioid use for specific patient populations. Where you see variability is in how prescribers manage transition from acute to chronic pain management. Some transition smoothly to non-opioid alternatives. Others hold opioids longer, waiting for a clear signal that deprescribing is justified.

The trend you should track is not whether opioids are being used, but whether individual claimants have a documented rationale for continued opioid therapy when claims enter chronic phases. Absence of deprescribing documentation often signals absence of deprescribing consideration.

Muscle Relaxants: Persistent Patterns

Muscle relaxant prescribing remains steady in workers compensation, with baclofen and tizanidine seeing consistent use, particularly in whiplash and lower back pain presentations. What's changed is understanding of their evidence base. Current literature suggests muscle relaxants have modest efficacy for acute musculoskeletal pain but limited evidence for chronic use beyond 2-3 weeks.

You're seeing claimants on muscle relaxants for months or years, well beyond the timeframe where evidence supports benefit. This is a manageable problem because it's visible and addressable. Your pharmacist-led review can clearly document when muscle relaxant continuation is unsupported by current evidence, giving your treating team a clear signal to consider deprescribing.

Antidepressants: Expanding Indications

Antidepressant prescribing in workers compensation has broadened. You see amitriptyline, venlafaxine, and duloxetine prescribed not only for concurrent mood disorders but as primary analgesic therapy for chronic pain, sleep disturbance, and anxiety related to injury. This expansion is evidence-based where it's specific. Amitriptyline has demonstrated benefit for neuropathic pain. Duloxetine shows efficacy in chronic pain management.

Your awareness should focus on whether these medications are being prescribed for a clear indication or whether they're functioning as general purpose treatments for injury-related distress. When an antidepressant is prescribed for pain without clear documentation of which pain type it's targeting, you're looking at imprecision that your claims strategy should address.

Benzodiazepine Use: The Persistent Problem

Benzodiazepine prescribing in workers compensation remains concerning despite decades of evidence supporting minimization. You see claimants who initiated benzodiazepines acutely and remain on them years later. The prescribing trajectory is predictable: acute prescription for anxiety or sleep, incremental dose escalation as tolerance develops, eventual recognition that deprescribing is needed, and often failure to achieve deprescribing due to dependence.

What distinguishes 2026 from earlier years is prescriber awareness that this is a problem. You're seeing explicit documentation that deprescribing is the goal, structured tapering plans, and often referral to addiction services for assistance. This represents genuine progress. However, you're also seeing claims where benzodiazepine dependence persists because tapering has stalled or failed.

Your claims strategy should treat benzodiazepine use as a key metric. If your claimant initiates benzodiazepines, that medication should have a documented expiration date. If it extends beyond that date, you need to understand why deprescribing hasn't occurred and what your role is in facilitating it.

Emerging Trend: Compound Prescriptions

Compounded medications are appearing with increasing frequency in workers compensation claims. Some represent evidence-based practice: low-dose naltrexone for chronic pain, ketamine creams for neuropathic pain. Others are less clearly supported by evidence. Your awareness should focus on whether compounded medications represent precision medicine optimized for individual claimant needs or whether they're emerging because conventional options have failed or prescriber preference has shifted toward commercial compounding services.

Compounded medications require particular scrutiny because they're usually more expensive than conventional pharmaceuticals, and their evidence base is frequently thinner. This isn't an argument against compounding; it's an argument for ensuring that when you're funding compounded medications, there's clear documentation that conventional alternatives have been attempted and failed.

Vaccines and Prevention: Increasing Uptake

You're seeing higher rates of vaccination in workers compensation populations, particularly for shingles and RSV in aging claimants. This represents positive prevention-focused practice. However, your awareness should extend to whether vaccination decisions are being made proactively as part of comprehensive injury management or reactively after preventable illness has complicated your claim. Proactive vaccination in the acute phase of injury management is far more cost-effective than managing complications years later.

Key Metrics for Your Claims Strategy

Monitor these prescription trends within your own claims population to understand whether national patterns are manifesting in your book:

What This Means for Your Claims Management

You should use these trends to shape your claims strategy proactively. If gabapentinoid escalation is the prevailing trend, your early claims management should establish clear documentation about escalation parameters before doses become entrenched. If benzodiazepine deprescribing is challenging in your population, your claims strategy should prioritize deprescribing planning from the moment these medications are prescribed, not years later when dependence is established.

The national trends you're observing allow you to anticipate problems before they become claims issues. You can implement preventive strategies: earlier referral for medication reviews, clearer guidance to your treatment networks about evidence-based dosing, and proactive deprescribing planning before medications become entrenched.

Conclusion: Anticipate, Don't React

The medication landscape in Australian workers compensation is dynamic. Understanding what's shifting, where evidence supports change, and where drift is occurring allows you to shape your claims management strategically. You're not simply observing prescribing trends; you're using those trends to anticipate which medications will become problematic in your claims and how to intervene before those problems entrench themselves.